Blogs » Health » The developer of sildenafil and the PDE5 Inhibitor as a prelude

The developer of sildenafil and the PDE5 Inhibitor as a prelude

  • No one can deny that Pfizer's sildenafil made a significant contribution to the development of male medicine and the pharmaceutical industry related to oral erectile dysfunction drugs.

    Pfizer's research team synthesized 비아그라 정품 in 1989 to develop a cardiovascular disease treatment using a selective PDE5 inhibitor in 1986 and began research and development as a treatment for pulmonary arterial hypertension and ischemic heart disease. Since 1990, various researchers have reported that PDE5 can act on the pulmonary vascular system, and Ignarro et al. reported that nitric oxide is also secreted as a neurotransmitter in the cavernous nerve of the penis during sexual stimulation.

    The R&D team of Pfizer Pharmaceuticals abandoned the development of UK-92380 (later named sildenafil), a selective PDE5 inhibitor, as a treatment for ischemic heart disease due to its relatively short duration of action and side effects caused by drug interactions with nitrates and started erection in 1993. 비아그라 정품, which is called the last invention of the 20th century, was born when it was redeveloped as a treatment for dysfunction and was approved by the FDA in 1998.

    The advent of 비아그라 정품 has given new momentum to the development of new drugs and the pharmaceutical industry, including the development of oral erection stimulants and diversification of indications. In fact, Lilly's Cialis and Bayer's Levitra were developed in 2004, and PDE5-Is sildenafil, vardenafil, and tadalafil have successfully treated more than 40 million patients with erectile dysfunction.

     In this process, the efficacy, safety, and tolerability of PDE5-Is have already been proven and based on this, cyclic GMP (cGMP), the master of intracellular signaling, and various physiological functions of PDE5 that regulate it, Research on the possibility of application has been actively conducted. Through this, sildenafil was approved by the US FDA and European Agency for the Evaluation of Medicinal Products (EAEMP) in 2005 as a treatment for pulmonary hypertension.

    PDE5-Is have begun to broaden the scope of indications in the battle for erectile dysfunction drugs, and in addition, to develop new treatments for diseases requiring chronic medication, PDE5-Is can be applied in various stages of preclinical studies for various new indications. started research and development.